Dermata Therapeutics Inc. Warrant (DRMAW)
$0.00
$0.00
(-50.00%)
As on 17-Aug-2026 12:16EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
5 Years Aggregate
CFO
$-28.89 Mln
EBITDA
$-33.20 Mln
Net Profit
$-33.76 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Dermata Therapeutics Inc. Warrant (DRMAW)
| -97.5 | -93.3 | -96.7 | -97.3 | -72.5 | -77.5 | -- |
|
BSE Sensex*
| -12.0 | -5.2 | 0.7 | -8.5 | 3.8 | 5.0 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Dermata Therapeutics Inc. Warrant (DRMAW)
| 124.7 | 52.5 | -52.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Dermata Therapeutics Inc. Warrant (DRMAW)
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment... products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Read more
-
Founder, President, CEO & Chairman
Mr. Gerald T. Proehl
-
Founder, President, CEO & Chairman
Mr. Gerald T. Proehl
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Dermata Therapeutics Inc. Warrant (DRMAW)
What is the current share price of Dermata Therapeutics Inc Warrant (DRMAW) Today?
The share price of Dermata Therapeutics Inc Warrant (DRMAW) is $0.00 (NASDAQ) as of 17-Aug-2026 12:16 EDT. Dermata Therapeutics Inc Warrant (DRMAW) has given a return of -72.45% in the last 3 years.
What is the current PB & PE ratio of Dermata Therapeutics Inc Warrant (DRMAW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
0.00 |
0.00 |
2024 |
0.00 |
0.00 |
2023 |
0.00 |
0.00 |
2022 |
0.00 |
0.00 |
2021 |
-0.05 |
0.04 |
What is the 52 Week High and Low of Dermata Therapeutics Inc Warrant (DRMAW)?
The 52-week high and low of Dermata Therapeutics Inc Warrant (DRMAW) are Rs 0.03 and Rs 0.00 as of 11-Sep-2026.
What is the market cap of Dermata Therapeutics Inc Warrant (DRMAW)?
Dermata Therapeutics Inc Warrant (DRMAW) has a market capitalisation of -- as on 17-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Dermata Therapeutics Inc Warrant (DRMAW)?
Before investing in Dermata Therapeutics Inc Warrant (DRMAW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.